Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 9, 2013, Pages 1162-1166

  Wang, J C ^a   He, L L ^a   Chen, Q ^a  

^a Nuclear Industry 416 Hospital   (China)

Author keywords

Chronic hepatitis B; Combination therapy; Entecavir; Lamivudine plus adefovir; Monotherapy; Retreatment; Viral relapse

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DNA VIRUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RELAPSE; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE;

ADENINE; ADULT; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER FUNCTION TESTS; MALE; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 84878564550     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. LAI CL, RATZIU V, YUEN MF, POYNARD T. Viral hepatitis B. Lancet 2003; 362: 2089-2094.
2. LAVANCHY D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis 2004; 11: 97-107.
3. VAN DAMME P, ZANETTI AR, SHOUVAL D, VAN HERCK K. Strategies for global prevention of hepatitis B virus infection. Adv Exp Med Biol 2010; 659: 175-188.
4. LIU TT, FANG Y, XIONG H, CHEN TY, NI ZP, LUO JF, ZHAO NQ, SHEN XZ. A case-control study of the relationship between hepatitis B virus DNA level and risk of hepatocellular carcinoma in Qidong, China.World J Gastroenterol 2008; 14: 3059-3063.
5. ILOEJE UH, YANG HI, SU J, JEN CL, YOU SL, CHEN CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
6. LOK AS, MCMAHON BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
7. ITO K, TANAKA Y, ORITO E, HIRASHIMA N, IDE T, HINO T, KUMASHIRO R, KATO A, NUKAYA H, SAKAKIBARA K, MUKAIDE M, ITO H, SATA M, UEDA R, MIZOKAMI M. Predicting relapse after cessation of lamivudine monotherapy for chronic hepatitis B virus infection. Clin Infect Dis 2004; 38: 490-495.
8. SONG BC, SUH DJ, LEE HC, CHUNG YH, LEE YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-806.
9. DIENSTAG JL, CIANCIARA J, KARAYALCIN S, KOWDLEY KV, WILLEMS B, PLISEK S, WOESSNER M, GARDNER S, SCHIFF E. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 748-755.
10. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chinese Med J (Engl) 2007; 120: 2159-2173.
11. ZOULIM F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int 2011; 31 Suppl 1: 111-116.
12. CAREY I, HARRISON PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2009; 18: 1655-1666.
13. EASL CLINICAL PRACTICE GUIDELINES: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
14. REIJNDERS JG, PERQUIN MJ, ZHANG N, HANSEN BE, JANSSEN HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139: 491-498.
15. CHEN EQ, WANG LC, LEI J, XU L, TANG H. Metaanalysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus.Virol J 2009; 6: 163.